Published in Chin J Cancer on April 19, 2013
Targeting insulin-like growth factor 1 receptor inhibits pancreatic cancer growth and metastasis. PLoS One (2014) 1.04
Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes Dis (2015) 1.01
Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways. Oncotarget (2014) 1.00
IGF-IR Targeted Therapy: Past, Present and Future. Front Endocrinol (Lausanne) (2014) 0.88
Targeting the IGF-1R: The Tale of the Tortoise and the Hare. Front Endocrinol (Lausanne) (2015) 0.87
Epithelial-to-mesenchymal transition in breast cancer: a role for insulin-like growth factor I and insulin-like growth factor-binding protein 3? Breast Cancer (Dove Med Press) (2015) 0.85
The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients. Int J Mol Sci (2015) 0.85
Current perspectives between metabolic syndrome and cancer. Oncotarget (2016) 0.84
Disruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cells. Oncogene (2016) 0.81
Inhibition of intracerebral glioblastoma growth by targeting the insulin-like growth factor 1 receptor involves different context-dependent mechanisms. Neuro Oncol (2014) 0.79
Molecular targeted agents--where we are and where we are going. Chin J Cancer (2013) 0.79
Growth hormone receptor inhibition decreases the growth and metastasis of pancreatic ductal adenocarcinoma. Exp Mol Med (2014) 0.79
Secreted IGFBP5 mediates mTORC1-dependent feedback inhibition of IGF-1 signalling. Nat Cell Biol (2016) 0.78
MiR-503 inhibits hepatocellular carcinoma cell growth via inhibition of insulin-like growth factor 1 receptor. Onco Targets Ther (2016) 0.78
NEDD4: a promising target for cancer therapy. Curr Cancer Drug Targets (2014) 0.78
Targeting Insulin Receptor with a Novel Internalizing Aptamer. Mol Ther Nucleic Acids (2016) 0.78
Toward precision medicine of breast cancer. Theor Biol Med Model (2016) 0.77
Vav2 protein overexpression marks and may predict the aggressive subtype of ductal carcinoma in situ. Biomark Res (2014) 0.77
Interplay between cell cycle and autophagy induced by boswellic acid analog. Sci Rep (2016) 0.77
Caloric restriction coupled with radiation decreases metastatic burden in triple negative breast cancer. Cell Cycle (2016) 0.77
Phase I dose-escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-573, a dual IGF-I/II neutralizing antibody, in Japanese patients with advanced solid tumours. Invest New Drugs (2014) 0.77
BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549. BMC Res Notes (2016) 0.77
Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management. Oncologist (2016) 0.77
Fibroblast subtypes regulate responsiveness of luminal breast cancer to estrogen. Clin Cancer Res (2016) 0.76
IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin. Oncotarget (2016) 0.76
Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification. J Cancer Res Clin Oncol (2016) 0.76
PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer. Sci Signal (2017) 0.75
Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism. Int J Mol Sci (2015) 0.75
miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. Genes Dev (2017) 0.75
Snail modulated miR - 493 forms a negative feedback loop with IGF1R pathway and blocks tumorigenesis. Mol Cell Biol (2016) 0.75
Co-Targeting IGF-1R and Autophagy Enhances the Effects of Cell Growth Suppression and Apoptosis Induced by the IGF-1R Inhibitor NVP-AEW541 in Triple-Negative Breast Cancer Cells. PLoS One (2017) 0.75
Recurrent, bilateral, and metastatic pheochromocytoma in a young patient with Beckwith-Wiedemann syndrome: A genetic link? Can Urol Assoc J (2017) 0.75
Implications of Insulin-like Growth Factor 1 Receptor Activation in Lung Cancer. Malays J Med Sci (2016) 0.75
Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors. BMC Cancer (2015) 0.75
MicroRNA-30a-5p inhibits the proliferation and invasion of gastric cancer cells by targeting insulin-like growth factor 1 receptor. Exp Ther Med (2017) 0.75
Hematopoietic Stem Cell-derived Adipocytes Promote Tumor Growth and Cancer Cell Migration. Int J Cancer Res Mol Mech (2017) 0.75
Picropodophyllin (PPP) is a potent rhabdomyosarcoma growth inhibitor both in vitro and in vivo. BMC Cancer (2017) 0.75
Glycosides from Stevia rebaudiana Bertoni Possess Insulin-Mimetic and Antioxidant Activities in Rat Cardiac Fibroblasts. Oxid Med Cell Longev (2017) 0.75
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer (2008) 11.50
Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science (2003) 6.85
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene (2006) 6.54
Insulin-like growth factors and neoplasia. Nat Rev Cancer (2004) 6.29
Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res (2005) 3.78
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol (2009) 3.21
A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res (2003) 3.09
Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res (2004) 2.90
Retracted Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol (2009) 2.75
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol (2009) 2.63
Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res (2007) 2.61
Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res (2005) 2.31
Insulin-like growth factors and cancer. Ann Intern Med (1995) 2.29
The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem (2008) 2.20
The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology (2002) 2.03
Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab (2007) 2.02
Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res (2002) 1.96
Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res (2007) 1.84
Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res (2012) 1.83
Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer (2005) 1.75
Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells. Breast Cancer Res Treat (2005) 1.72
Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol (2008) 1.64
The IGF-I receptor in cancer research. Exp Cell Res (1999) 1.64
Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol (2011) 1.63
BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther (2009) 1.62
Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res (2007) 1.61
Requirement of estrogen receptor-alpha in insulin-like growth factor-1 (IGF-1)-induced uterine responses and in vivo evidence for IGF-1/estrogen receptor cross-talk. J Biol Chem (2001) 1.60
Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res (1990) 1.57
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol (2009) 1.50
In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res (2001) 1.46
Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol (2012) 1.46
Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol (2011) 1.45
Involvement of insulin-like growth factor-I in the control of glucose homeostasis. Curr Opin Pharmacol (2006) 1.39
Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk. Cancer Res (2005) 1.39
A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res (2011) 1.36
Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death--proliferative and anti-apoptotic effects. Breast Cancer Res Treat (1999) 1.33
Insulin receptor expression and function in human breast cancer cell lines. Cancer Res (1992) 1.31
Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Res (2011) 1.22
Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res (2005) 1.22
Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene (1995) 1.22
Insulin-like growth factor II stimulates cell proliferation through the insulin receptor. Proc Natl Acad Sci U S A (1997) 1.19
Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res (2004) 1.18
Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood (2000) 1.17
Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth. Endocr Relat Cancer (2005) 1.16
Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. Cancer Res (1992) 1.14
Insulin-like growth factors and breast cancer. Biomed Pharmacother (1995) 1.01
Type 1 IGF receptor in human breast diseases. Breast Cancer Res Treat (1992) 1.00
Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody. Mol Cancer Ther (2011) 1.00
Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). Cancer Treat Rev (2011) 0.91
Modification of insulin-like growth factor 1 receptor, c-Src, and Bcl-XL protein expression during the progression of Barrett's neoplasia. Hum Pathol (2003) 0.89
The insulin-like growth factor system as a therapeutic target in colorectal cancer. Ann Oncol (2002) 0.88
A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. BJU Int (2008) 0.88
Combined effects of tamoxifen and a chimeric humanized single chain antibody against the type I IGF receptor on breast tumor growth in vivo. Horm Metab Res (2004) 0.87
Activity of fulvestrant in HER2-overexpressing advanced breast cancer. Ann Oncol (2009) 0.87
Development of strategies for the use of anti-growth factor treatments. Endocr Relat Cancer (2005) 0.85
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med (2013) 2.39
Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res (2010) 1.59
Mesothelin-targeted agents in clinical trials and in preclinical development. Mol Cancer Ther (2012) 1.47
Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts. Clin Cancer Res (2011) 1.04
Fibulin-3 as a biomarker for pleural mesothelioma. N Engl J Med (2013) 0.92
Chemotherapy and targeted therapies for unresectable malignant mesothelioma. Lung Cancer (2011) 0.91
Thyroid cancer presentation and treatment in the United States. Ann Surg Oncol (2014) 0.75
Metastatic Melanoma: Treatment and Survival in the US after the Introduction of Ipilimumab and Vemurafenib. Oncol Res Treat (2017) 0.75
The future of cancer prevention: ripe for a revolution. Future Oncol (2006) 0.75
Lymphangiomatosis with dental involvement. Lymphat Res Biol (2014) 0.75